Liebe Kolleginnen und Kollegen,wir freuen uns sehr, Sie zum CVOT Summit 2024 (Congress on Cardiovascular, Kidney and Metabolic Outcomes) einzuladen, der als virtueller Kongress am 5. und 6. Dezember 2024 aus München übertragen wird. Der CVOT Summit findet zum 10. Mal statt. Unter www.cvot.org können Sie sich kostenfrei registrieren.

Der virtuelle Kongress ist eCME-zertifiziert. Wir freuen uns zu sehen, dass der CVOT Summit wächst und sich weiterentwickelt. Immer mehr wissenschaftliche Gesellschaften kooperieren mit dem CVOT Summit und wir konnten wieder eine hervorragende Faculty gewinnen, dem Kongress beizutragen. Wie bei unseren früheren CVOT Summits freuen wir uns darauf, ein breites Publikum von Kardiologen, Nephrologen, Diabetologen, Endokrinologen und Allgemeinmedizinern aus der ganzen Welt begrüßen zu dürfen. Unserer Tradition folgend, wird der Virtual CVOT Summit 2024 die neuesten Entwicklungen und Nachrichten in den verschiedenen Bereichen der Forschung und der klinischen Praxis im Zusammenhang mit kardiovaskulären, nieren- und stoffwechselbedingten Ergebnissen behandeln. Seien Sie dabei, wenn hochkarätige Fachleute und Experten aus der ganzen Welt über die neuesten Studien, wissenschaftlichen Untersuchungen, klinischen Leitlinien und praktischen Empfehlungen berichten.Gemeinsam mit dem Organisationsteam freue ich mich darauf, Sie beim diesjährigen CVOT Summit 2024 virtuell begrüßen zu dürfen.

Thursday, 5 December 2024 (Virtual)

15:30 – 15:40 CET Welcome and Introduction; Oliver Schnell (Munich, Germany)

15:40 – 17:15 CET Cardiovascular, kidney and metabolic care: Current and future perspectives; Chairs: Luc van Gaal (Antwerp, Belgium), Paola Fioretto (Padua, Italy)

  • - 15:40 – 15:55 Update on the treatment of heart failure - new approaches, new outcomes; Mikhail Kosiborod (Kansas City, US)
  • - 15:55 – 16:10 Chronic kidney disease: Cornerstones of today´s treatment and opportunities for the future; Beatriz Fernández-Fernández (Madrid, Spain)
  • - 16:10 – 16:25 The next decade in the treatment of obesity; Barbara McGowan (London, UK)
  • - 16:25 – 16:45 Organ Cross-Talk and Person-Centered Management of Obesity, CKD, Lipid Disorders, and Diabetes; Dirk Müller-Wieland (Aachen, Germany)
  • - 16:45 – 17:00 Microplastics and nanoplastics (MNPs): An emerging risk factor for cardiovascular disease; Antonio Ceriello (Milan, Italy)
  • - 17:00 – 17:15 Panel Discussion

17:15 – 17:30 Break

17:30 – 18:45 CET Updates from the Taskforce of the Guideline Workshop; Chairs: Helena Rodbard (Rockville, USA), Lars Rydén (Stockholm, Sweden)

  • - 17:30 – 17:45 The Taskforce of the Guideline Workshop: Aims and outcomes; Oliver Schnell (Munich, Germany)
  • - 17:45 – 18:00 Towards standardization of patient reported outcomes (PROs); Katharine Barnard-Kelly (Hampshire, UK)
  • - 18:00 – 18:15 Disparities in prevalence and treatment of diabetes, cardiovascular and chronic kidney diseases; James R. Gavin (Atlanta, USA)
  • - 18:15 – 18:30 Network meta-analyses and clinical guidelines: what is missing for a precision medicine approach; Francesco Giorgino (Bari, Italy)
  • - 18:30 – 18:45 Discussion

18:45 – 19:00 Break

19:00 – 20:00 CET Cardio-renal metabolic diseases: How can we connect the dots? Chair: Sarah Jarvis (London, UK) Satellite Symposium kindly supported by Boehringer Ingelheim

  • - 19:00 – 19:03 Welcome and introduction; Sarah Jarvis (London, UK)
  • - 19:03 – 19:13 Why does connecting the dots matter in CRM diseases? Nikolaus Marx (Aachen, Germany)
  • - 19:13 – 19:23 Connecting the dots in understanding CRM disease: does aldosterone have a role? Per-Henrik Groop (Helsinki, Finland)
  • - 19:23 – 19:33 Connecting the dots in CRM disease: how do we work together? Sarah Jarvis (London, UK)
  • - 19:33 – 19:58 Panel discussion
  • - 19:58 – 20:00 Closing remarks/final thoughts; Sarah Jarvis (London, UK)
  • - 20:00 – 20:45 CET Oral Presentations – Part 1; Chairs: tbd

20:45 Closing Day 1; Oliver Schnell (Munich, Germany)

Friday, 6 December 2024 (Virtual)

08:30 – 09:30 CET Type 1 Diabetes – Early detection and preventive treatment approaches; Chairs: Chantal Mathieu (Leuven, Belgium), Othmar Moser (Bayreuth, Germany)

  • - 08:30 – 08:45 Early detection of Type 1 Diabetes - risk evaluation, markers and early diagnosis programs; Thomas Danne (Lisbon, Portugal)
  • - 08:45 – 09:00 Treatment strategies for delaying the onset of Type 1 Diabetes; Colin M. Dayan (Cardiff, UK)
  • - 09:00 – 09:15 Future directions in the treatment of CKD in Type 1 Diabetes; Hiddo Heerspink (Groningen, Netherlands)
  • - 09:15 – 09:30 Discussion

09:30 – 10:45 CET Advancing diabetes management through technological innovations; Chairs: Tadej Battelino (Ljubljana, Slovenia), Doina Catrinoiu (Constanta, Romania)

  • - 09:30 – 09:45 Continuous glucose monitoring in Type 2 Diabetes; Stefano del Prato (Pisa, Italy)
  • - 09:45 – 10:00 CGM and cardiovascular perspectives; Ulf Landmesser (Berlin, Germany)
  • - 10:00 – 10:15 CGM, hypoglycemia and risk prediction; Lutz Heinemann (San Diego, US)
  • - 10:15 – 10:30 Automated Insulin delivery (AID), physical activity and exercise in Type 1 Diabetes; Othmar Moser (Bayreuth, Germany)
  • - 10:30 – 10:45 Discussion

10:45 – 11:00 Break

11:00 – 12:00 CET CKD and heart failure: current perspectives on diagnosis and treatment; Chair: Per-Henrik Groop (Helsinki, Finland)

  • - 11:00 – 11:15 UACR and eGFR: barriers of implementation; Elke Schäffner (Berlin, Germany)
  • - 11:15 – 11:30 KDIGO guidelines 2024: consistence with ESC? Michel Jadoul (Brussels, Belgium)
  • - 11:30 – 11:45 REVOLUTIONizing heart failure diagnosis; Lisa Anderson (London, UK)
  • - 11:45 – 12:00 Discussion

12:00 – 12:30 CET Diabetes and the heart: exploring effects beyond heart failure; Chairs: Nikolaos Papanas (Alexandroupolis, Greece), Boris Mankovsky (Kyiv, Ukraine)

  • - 12:00 – 12:10 Cardiac autonomic neuropathy: current experimental and clinical practice considerations; Alin Stirban (Birkenwerder, Germany)
  • - 12:10 – 12:20 Mitochondrial metabolomics and the diabetic heart; Eberhard Standl (Munich, Germany)
  • - 12:20 – 12:30 Discussion

12:30 – 13:30 CET Primary care at the forefront of cardiorenal and metabolic disease management; Chairs: Dipesh Patel (London, UK), Pinar Topsever (Istanbul, Turkey)

  • - 12:30 – 12:45 Cardiovascular Risk evaluation in primary care; Naresh Kanumilli (Manchester, UK)
  • - 12:45 – 13:00 Interconnectedness of Heart, Kidney and Metabolism – Perspectives of PCPs; Xavier Cos (Barcelona, Spain)
  • - 13:00 – 13:15 Empowering diabetes self-management: the path to success; Tatjana Milenkovic (Skopje, Macedonia)
  • - 13:15 – 13:30 Discussion

13:30 – 14:00 Break

14:00 – 14:45 CET Targeting obesity – combating metabolic diseases; Chairs: Luca Busetto (Padua, Italy), Matthias Blueher (Leipzig, Germany)

  • - 14:00 – 14:15 Obesity as a therapeutic target in heart failure therapy; Luc van Gaal (Antwerp, Belgium)
  • - 14:15 – 14:30 GIP/GLP-1 receptor agonists – a new dawn in sleep apnea therapy?; Igor Harsch (Saalfeld, Germany)
  • - 14:30 – 14:45 Discussion

14:45 – 15:30 CET Eating for Health: Nutritional Strategies in Metabolic and Cardiovascular Care; Chairs: Linong Ji (Beijing, China), Dario Rahelić (Zagreb, Croatia)

  • - 14:45 – 15:00 On the Path to Precision Nutrition in Cardiometabolic Diseases; Andreas Pfeiffer (Potsdam, Germany)
  • - 15:00 – 15:15 Navigating Nutrition under Incretin-Based Therapies; Jaime Almandoz (Texas, USA)
  • - 15:15 – 15:30 Discussion

15:30 – 16:15 CET Liver in the Spotlight: Current Practices and New Horizons; Chairs: Frank Tacke (Berlin, Germany), Linong Ji (Beijing, China)

  • - 15:30 – 15:45 Diagnosis and Treatment of MASLD: Current State of the Art; Wendy Spearman (Cape Town, South Africa)
  • - 15:45 – 16:00 The liver – a new target for incretin therapies? Frank Tacke (Berlin, Germany)
  • - 16:00 – 16:15 Discussion

16:15 – 16:30 Break

16:30 – 17:30 CET Industry’s perspective - Panel Discussion; Oliver Schnell (Munich, Germany)

17:30 – 18:30 CET Oral Presentations – Part 2; Chair: Thomas Forst (Mainz, Germany)

18:30 – 18:45 CET Abstract Award and Closing; Oliver Schnell (Munich, Germany)


Erschienen in: Diabetes, Stoffwechsel und Herz, 2024; 33 (6) Seite 357-362